Celldex Therapeutics, Inc.
CLDX· Nasdaq
Released Aug 6, 2026, after the close
10-Q filed Aug 6, 2026, 37 days after period end · 0001104659-26-091984
| Metric | Q2 2026 | Q2 2025 | Q2 2024 | Q2 2023 |
|---|---|---|---|---|
| Revenue | $22.00K | $730.00K | $2.50M | $268.00K |
| Net Income | -$73.50M | -$56.60M | -$35.84M | — |
| EPS Diluted |
Celldex Therapeutics, Inc. · CIK 744218 · Engraved from SEC EDGAR
| -$0.94 |
| -$0.85 |
| -$0.54 |
| -$0.65 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.